Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pureos Bioventures is a Switzerland-based venture capital firm focused on investing in private companies that develop innovative drug therapies. The firm specializes in the biopharmaceutical sector, with a portfolio of 20 companies and a commitment to advancing treatments for severe diseases. Their investment strategy emphasizes clinical-stage and preclinical companies.
Pureos Bioventures invests in pre-seed, seed, and Series A stages, primarily targeting biotech and healthcare sectors. They back companies developing novel therapeutics for severe diseases, including cancer, fibrotic diseases, and neurological disorders. Typical investments are directed towards clinical-stage and preclinical companies working on innovative drug formats.
Notable companies in Pureos Bioventures' portfolio include Acrivon Therapeutics, Adcytherix, and Alentis Therapeutics. Significant exits include Araris Biotech, acquired by Taiho Pharmaceutical, and Corlieve Therapeutics, acquired by uniQure. ImCheck Therapeutics was also acquired by Ipsen.
Submit your pitch through their website's contact form for consideration.
Yes, Pureos Bioventures often leads investment rounds, particularly in the early stages of funding for biotech companies.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress in their clinical development.
Specific details about the size of their current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.